<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intravenous pharmacologic agents for acute heart rate control in patients with atrial fibrillation and chronic obstructive pulmonary disease*</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup width="40%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Loading dose</td> <td class="subtitle1">Onset</td> <td class="subtitle1">Maintenance dose (for initial 24 to 72 hours)</td> <td class="subtitle1">Major side effects</td> </tr> <tr> <td class="subtitle2_left" colspan="5">There is evidence and/or general agreement that the following drugs are effective for acute heart rate control in patients with AF who do NOT have an accessory pathway or heart failure</td> </tr> <tr> <td class="indent1">Verapamil<sup>¶</sup></td> <td>0.075 to 0.15 mg/kg (usually 5 to 10 mg/dose [maximum 10 mg]) IV over 2 to 3 minutes, may repeat dose in 15 to 30 minutes if inadequate response to initial dose</td> <td>3 to 5 minutes</td> <td> </td> <td>Hypotension, heart block, heart failure</td> </tr> <tr> <td class="indent1">Diltiazem<sup>¶</sup></td> <td>0.25 mg/kg IV (average adult dose 20 mg) over 2 minutes, may repeat with a higher dose of 0.35 mg/kg IV (average adult dose 25 mg) in 15 to 30 minutes if inadequate response to initial dose</td> <td>2 to 7 minutes</td> <td>5 to 15 mg/hour IV infusion titrated according to ventricular heart rate</td> <td>Hypotension, heart block, heart failure</td> </tr> <tr class="divider_bottom"> <td class="indent1">Metoprolol<sup>¶</sup><sup>Δ</sup><sup>◊</sup></td> <td>2.5 to 5 mg IV over 2 minutes; up to 3 doses (maximum 15 mg total) administered 5 to 10 minutes apart may be given</td> <td>5 minutes</td> <td> </td> <td>Hypotension, heart block, bradycardia, heart failure, bronchoconstriction</td> </tr> <tr> <td class="subtitle2_left" colspan="5">For acute heart rate control in patients with AF and an accessory pathway</td> </tr> <tr class="divider_bottom"> <td class="indent1">Amiodarone<sup>¶</sup><sup>§</sup></td> <td>150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours</td> <td>1 to 30 minutes</td> <td>0.5 mg/minute IV infusion for up to additional 48 hours</td> <td>Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity</td> </tr> <tr> <td class="subtitle2_left" colspan="5">For acute heart rate control in patients with AF and heart failure but not an accessory pathway</td> </tr> <tr> <td class="indent1">Digoxin<sup>¶</sup><sup>¥</sup><sup>‡</sup></td> <td>0.25 mg IV every 2 hours, up to a total dose of 1.5 mg</td> <td>15 to 30 minutes, peak effect in 1 to 5 hours</td> <td>0.125 to 0.25 mg orally once a day</td> <td>Digitalis toxicity, heart block, bradycardia</td> </tr> <tr> <td class="indent1">Amiodarone<sup>¶</sup><sup>§</sup></td> <td>150 mg IV over 30 minutes, followed by 1 mg/minute IV infusion for 6 hours, followed by 0.5 mg/minute IV infusion for 18 hours</td> <td>1 to 30 minutes</td> <td>0.5 mg/minute IV infusion for up to additional 48 hours</td> <td>Hypotension, sinus bradycardia, heart block, QT prolongation, ventricular arrhythmias, pulmonary toxicity</td> </tr> </tbody></table></div><div class="graphic_footnotes">* For patients with hemodynamic instability due to atrial fibrillation, direct current cardioversion is the treatment of choice. For all patients with COPD and atrial fibrillation with a rapid ventricular response, correction of hypoxemia, acidosis, and other metabolic disturbances is recommended. Theophylline can increase the ventricular response, so dosing should be regulated to keep the serum level in the range of 8 to 12 mg/mL; discontinuation of the medication should be considered.<br/>¶ Electrocardiographic (ECG or telemetry) and blood pressure monitoring should be continuously performed during initial loading dose and frequently (eg, every 4 hours) during maintenance intravenous dosing.<br/><span class="lozenge">◊</span> Representative of the type of selective beta-1 blockers that could be used but similar drugs could be given in appropriate doses.<br/>Δ Nondihydropyridine calcium channel antagonists (eg, verapamil, diltiazem) are preferred over metoprolol for heart rate control of atrial fibrillation in patients with COPD due to concerns about exacerbating bronchoconstriction.<br/>§ Amiodarone can be useful when other measures are unsuccessful or contraindicated. For patients with an accessory pathway, intravenous amiodarone can be given if the rhythm cannot be converted or ablated and rate control is needed. <br/>¥ There is evidence and/or general agreement that digoxin is effective in patients with heart failure but not an accessory pathway.<br/>‡ Dosing shown is for normal renal function and normal body weight. Reduced doses are needed for renal insufficiency or low body weight. Refer to topic on "Method of digitalization".</div><div id="graphicVersion">Graphic 83353 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
